• KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
  • KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
  • KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
  • KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
  • KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
  • KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
  • KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
  • KZT/USD = 0.00218
  • TJS/USD = 0.10860
  • UZS/USD = 0.00008
  • TMT/USD = 0.29850
22 November 2026

Viewing results 13 - 18 of 50

Kazakhstan Emerges as Regional Leader in Medical Tourism

Kazakhstan has taken the lead in the post-Soviet space in terms of the rapid development of medical tourism, surpassing its closest regional competitors, according to Kristina Krivets, President of the Kazakhstan Medical Tourism Association. Rapid Growth in Patient Numbers The sector has experienced explosive growth in recent years. In 2022, when the association was first established, just 1,280 medical tourists were recorded. By 2023, that figure had jumped to 8,000 and by 2024, it reached 80,000. “This is a very sharp increase, which shows that Kazakhstan is becoming a notable player in the region,” Krivets said. According to the association, around 90% of foreign patients come from neighboring countries, Kyrgyzstan, Russia, Uzbekistan, plus nearby Tajikistan. The remaining 10% hail from countries such as the United States, Germany, Israel, Austria, and Switzerland. The most in-demand services include reproductive medicine, dentistry, and aesthetic procedures. Kazakhstan offers these treatments at lower costs while maintaining acceptable standards of quality. In parallel, there is growing interest in more complex procedures such as cardiac surgery, neurosurgery, and radiation therapy for cancer. The average bill for a foreign patient is approximately 1.5 million KZT ($2,780) for medical services alone. However, the total spending per patient is roughly ten times higher than that of a typical tourist, once accommodation, transportation, and additional services are factored in, underscoring the sector’s growing economic significance and its multiplier effect on related industries. Meeting International Standards Currently, nine clinics in Kazakhstan hold Joint Commission International (JCI) accreditation, seven in Astana and two in Almaty. While the accreditation process is costly and time-consuming, it is seen as essential for attracting international patients. “Today, Kazakhstan ranks first in medical tourism in Central Asia. Our main competitor is Uzbekistan, but we have every reason to become a medical tourism hub not just for our neighbors, but for a broader international audience,” Krivets stated. To help position Kazakhstan globally, the first international medical tourism exhibition, GlobalMedKZ, will be held in Astana on November 27-28. The event will focus on promoting the sector through information tours, social media campaigns, participation in international exhibitions, and consultations with foreign doctors. “GlobalMedKZ will become a platform for Kazakhstan to be known to the whole world,” Krivets emphasized. Legal Barriers Remain Despite its rapid development, the sector still faces significant legal challenges. Krivets pointed out that medical tourism is not yet defined in Kazakh legislation. “We are working with the Ministry of Health to include a definition in the Law ‘On Health,’ but ideally, a separate law on medical tourism is needed,” she said. Visa access is not a major hurdle, as most citizens from countries in Eurasia can enter Kazakhstan without a visa. However, state medical institutions are currently prohibited from paying commissions to foreign agents, limiting efforts to attract more international patients. Still, Krivets remains optimistic. “Medical tourism is a paid service that, with a well-structured system, can generate substantial revenue for the state. We see successful models in Turkey and South Korea, where it has become one of...

Tajikistan’s Pharmaceutical Sector Remains Heavily Dependent on Imports

Despite possessing vast reserves of medicinal plants, Tajikistan's pharmaceutical industry remains heavily reliant on imports. Experts are increasingly questioning why the sector has been reduced to a basic "buy-and-sell" model and what is hindering the use of the country’s natural resources. Abundant Resources, Limited Output Tajikistan is home to more than 3,500 species of medicinal plants, including licorice, mint, valerian, chamomile, motherwort, and even rare saffron. However, this natural wealth has not translated into pharmaceutical independence. In the past two years alone, Tajikistan has imported roughly $84 million worth of medicines. Currently, 67 pharmaceutical companies are registered in the country, producing around 600 types of drugs. Still, imported pharmaceuticals dominate the market. According to industry observers, the sector has evolved into a retail-focused trade, rather than a hub for research-based production. During the Soviet era, pharmaceuticals in Tajikistan were closely integrated with scientific institutions. Research institutes flourished, pharmacies compounded custom medications, and both training and quality control were rigorous. Following the collapse of the USSR, this infrastructure disintegrated. The responsible state committee was dissolved, and a previously regulated system was replaced by an unstructured market. Today, training programs are often accelerated, pharmacists’ qualifications are inconsistent, and the emphasis has shifted from treatment to sales. A Pharmacy That Heals Amid this decline, one notable exception is found in the city of Isfara, where a phytotherapy department has been established at the local hospital. Spearheaded by pharmacist Abubakr Faiziev, the department operates out of a restored facility where locally gathered herbs are used to produce traditional infusions and decoctions. Faiziev personally collects about half of the ingredients. “It is important to me that the pharmacy heals, not just sells,” he said. According to Faiziev, approximately 80% of patients return for follow-up treatment, often bypassing conventional doctors due to the perceived effectiveness of herbal therapies, a sentiment echoed even among members of the local elite. A Science in Decline Faiziev laments the erosion of scientific ambition in the country. "People now ask for business plans and guaranteed profits instead of pursuing knowledge. But science doesn’t work that way," he said. Research, he noted, has become sporadic and often relies on outdated data, with little interest from private companies in investing in innovation. Young professionals, too, are increasingly opting for commercial routes. “They prefer to open pharmacies for fast income rather than engage in research,” he explained. “There are many pharmacists now. But we must transform quantity into quality. Without passion for the profession, one cannot become a skilled expert.” The State’s Role and Untapped Potential President Emomali Rahmon has repeatedly stressed the need to develop the domestic pharmaceutical industry and better utilize Tajikistan’s natural resources. Ongoing reforms include updates to medical university curricula, the opening of laboratories, and the training of technologists and quality control specialists. Yet, experts argue that without a comprehensive, systematic strategy and active engagement from the private sector, these measures are insufficient. Faiziev advocates for the creation of a pharmaceutical technology park and the development of both the domestic...

UNICEF Delivers Over 500 Pieces of Medical Equipment to Tajikistan

The United Nations Children's Fund (UNICEF) has handed over more than 500 units of modern medical equipment to the Ministry of Health and Social Protection of the Population of Tajikistan in a significant move to bolster the country's healthcare system. The official handover ceremony took place on May 6 in Dushanbe and was attended by Deputy Health Minister Shodikhon Jamshed and international partners. Jamshed expressed gratitude for UNICEF’s longstanding cooperation, adding that such support plays a vital role in strengthening Tajikistan’s healthcare capacity. The new equipment, including CPAP (Continuous Positive Airway Pressure) machines and oxygen concentrators, will be used to treat newborns with respiratory difficulties and patients requiring oxygen therapy. “The equipment will be distributed across 73 neonatal care facilities nationwide. Additionally, training courses will be held for healthcare workers on using these devices and providing respiratory care to newborns,” Jamshed stated. Since its founding in 1946, UNICEF has been active in Tajikistan through various initiatives aimed at advancing children's rights and improving access to essential services such as education and healthcare. One of its flagship efforts includes a $1 million juvenile justice reform project, implemented in partnership with the Swiss government. The initiative seeks to establish alternative measures for minors in conflict with the law, focusing on rehabilitation and reintegration. In the field of early education, UNICEF and USAID are implementing a five-year, $7.5 million program to enhance school readiness. This includes teacher training, updated educational materials, and the promotion of inclusive learning environments. To address malnutrition, UNICEF has launched a three-year program in Khatlon and Dushanbe aimed at improving maternal and child nutrition and reducing mortality. Emphasis is placed on primary healthcare and preventive measures. In collaboration with the European Union, UNICEF is also contributing to the restoration of medical infrastructure. One example is the refurbishment of the central district hospital in Tursunzade, part of Tajikistan’s National Health Strategy 2030, designed to expand access to essential health services across the country.

Kazakhstan Cancer Drug Could Hit the Market This Year

Kazakhstan’s Minister of Science and Higher Education, Sayasat Nurbek, has announced the development of a domestic anti-cancer drug currently undergoing clinical trials. According to Nurbek, Phase II clinical trials were completed in 2023, and the number of patients participating in the testing has since been significantly expanded. "At the moment, the drug is being tested on different types of cancer. Last year, trials were conducted exclusively on patients with colorectal cancer. By the end of 2024, we expect the drug to be officially registered and introduced to the market. Preliminary results indicate stable positive dynamics," the minister stated. He noted that patients in clinical trials have experienced remissions, with tumor sizes decreasing by an average of 30%. "By the end of the year, we plan to hold a conference to present the results. The Ministry of Health has been highly supportive, and we have optimized the registration process without violating regulations," Nurbek added. The official registration of the drug is expected to be finalized as soon as possible. Kazakhstan's development of its first domestically produced anti-cancer drug was first reported in January 2024. Later, Nurbek provided updates on the trial progress and expressed confidence in the drug’s effectiveness.

Kazakh Researchers Uncover Important Step Towards Treating Parkinson’s Disease

Kazakhstan’s reputation in the global scientific community is evolving, thanks to research conducted by local scientists. Aizhan Ahmadi, a doctoral graduate from Nazarbayev University’s (NU) School of Natural, Social, and Human Sciences, and her team have made a discovery that could pave the way for future treatments for Parkinson’s disease. TCA: Tell us about your research. Aizhan: I recently completed my doctoral studies, defended my dissertation, and earned my PhD. Before that, I worked at a university for five years. During my research, I focused on a mutated protein called DJ-1, which is found in patients with Parkinson’s and Alzheimer’s diseases. More than 20 years ago, European scientists identified mutations in DJ-1 in some patients suffering from these diseases. Despite extensive research in dozens of laboratories, the protein’s exact role remained unclear. While analyzing previous studies, we came across a large European research project with an interesting hypothesis about DJ-1. We decided to explore this direction further and we succeeded in proving that DJ-1 has a previously unknown function. Understanding how DJ-1 protects biomolecules is not only crucial for developing new treatment methods for Parkinson’s disease but also for explaining cell aging. This discovery is vital for pharmacologists, as they cannot develop effective drugs without fully understanding a protein’s function. For the first time, we have proven a new function of DJ-1. I believe this is a fundamental breakthrough for both global science and Kazakhstan’s scientific community. We submitted our findings to Nature Communications, a leading scientific journal. After a rigorous eight-month review process, our research was accepted. This was a difficult but rewarding journey. Our study is the first from independent Kazakhstan to be published in such a prestigious journal, making it a landmark achievement for our country. TCA: What challenges come with studying biology in Kazakhstan? Aizhan: Basic biological research is extremely resource-intensive. It takes time, energy, and has no guaranteed results. We invested grant funding and used millions of dollars’ worth of equipment. However, when a discovery is made, its contribution to science and medicine is invaluable. Our study was conducted entirely within Kazakhstan, without relying on foreign laboratories. This is particularly significant because many still doubt whether serious scientific breakthroughs can come from Kazakhstan, especially in biochemistry. Alongside me, my supervisor, Darkhan Utepbergenov, and several undergraduate students participated in the research. Professor Utepbergenov, a Kazakhstani scientist, graduated from Novosibirsk State University, worked in Germany and the U.S. for nearly 20 years, and then returned to Kazakhstan as a professor. He has said that this is his most significant work to date, and even he still finds it hard to believe that such a discovery was made in Kazakhstan. His contribution to both research and teaching at Nazarbayev University has been immense. TCA: As a young woman in science, what motivated you to pursue this path? How can Kazakhstan raise the status of scientists? Aizhan: First and foremost, better financial support is essential. Salary structures need improvement, bureaucratic obstacles must be reduced, and science communication should be...

Proposal to Ban Sex Change Operations in Kazakhstan

Kazakhstan's Mazhilis (Parliament) Deputy Magerram Magerramov has proposed a ban on sex change operations, arguing that such procedures contradict national culture, traditions, and common sense. Magerramov stressed the need to preserve traditional family values and questioned Kazakhstan’s legal framework, which currently allows gender reassignment for individuals diagnosed with gender dysphoria. “According to the Code of the Republic of Kazakhstan ‘On the Health of the People and the Health Care System’, citizens over 21 years old who do not have mental or behavioral disorders can change their gender identity. However, the very term ‘gender identity disorder’ already implies the presence of a certain deviation,” he said. The deputy argued that if a person has no physical abnormality but is diagnosed with an identity disorder, it should be classified as a mental or behavioral condition rather than grounds for medical intervention. “Interfering with a healthy body through hormone therapy and surgical procedures cannot be justified when it comes to mental or behavioral disorders. It is an attempt to bring the body in line with the subjective perception of reality, which, in my opinion, is unacceptable,” he added. Magerramov also expressed concerns about the impact on social norms, saying that gender transition was influenced by ideas unacceptable to Kazakh culture. The World Health Organization (WHO), however, removed transgender identity from the list of mental illnesses in its International Classification of Diseases (ICD-11) in 2019. Magerramov’s speech is not the first time he has criticized what he refers to as "Western values." Earlier, he accused foreign sponsors, particularly USAID, of funding women’s marches and LGBT events in Almaty. In addition, his colleague from the People’s Party of Kazakhstan, MP Irina Smirnova, has proposed a law on foreign agents, which would require media and NGOs to disclose sources of foreign funding.